Epigenetic and microRNA-mediated regulation of pulmonary fibrosis and immune dysregulation in fatal COVID-19 Authors: Gabriela Casani Cardoso, Regiane Stafim da Cunha, Guilherme Miniskiskosky, Cleber Machado-Souza, Lucia de Noronha, Caroline Busatta Vaz de Paula, Felipe Francisco Tuon, Edneia Amancio de Souza Ramos Cavalieri Published: 2026 ABSTRACT BackgroundSevere cases of COVID-19 can result in acute respiratory distress syndrome, extensive lung damage, and long-term structural changes, particularly extracellular matrix (ECM) remodeling. ECM remodeling is characterized by excessive collagen deposition and imbalanced activity of enzymes, such as matrix metalloproteinases. Although immune and inflammatory pathways in patients with COVID-19 are well understood, the epigenetic and post-transcriptional regulation is not well understood. In this exploratory study, we examined DNA methylation and miRNA-mediated regulation in lung tissues from fatal cases of COVID-19.MethodsMethods included gene and protein expression analyses, DNA methylation assays, evaluation of DNMT activity, MSP‒dPCR, miRNA profiling and pathway enrichment analysis.ResultsWe observed altered expression of ECM regulators, such as MMP2, MMP9 and ADAM33, as well as molecules related to SARS-CoV-2 infection, including ADAM17 and ACE2. Evidence of methylation-mediated regulation was observed for ADAM33 and ACE2. Two miRNAs were significantly downregulated (miR-16-5p and miR-30d-5p), whereas miR-19a-3p/19b-3p and miR-21-5p were upregulated. Pathway analysis revealed activation of p53, apoptosis, and growth factor related pathways, as well as the suppression of vascular, interferon and T-cell activation signaling pathways.ConclusionOverall, these findings suggest that, in this cohort of fatal COVID-19 cases, lung tissue exhibits features consistent with ECM remodeling, epithelial fibrosis, and immune dysregulation. Additionally, the results raise the possibility that epigenetic alterations and miRNA-mediated regulatory mechanisms may be associated with disease progression in severe cases.Graphical Abstract Supplementary InformationThe online version contains supplementary material available at 10.1186/s10020-026-01467-8. Background COVID-19, caused by SARS-CoV-2, varies in severity from mild symptoms to severe complications, including pneumonia, acute respiratory distress syndrome (ARDS) and death, with potential long-term damage to multiple organ systems (Al-Aly et al. 2021). Its pathogenesis involves various mechanisms, including inflammation and extracellular matrix (ECM) remodeling. Some ECM proteins important for understanding pulmonary fibrosis, such as the metalloproteases MMP2, MMP9, ADAM33 and ADAM17, are dysregulated and have been implicated in pulmonary diseases, including COVID-19 severity (Wang et al. 2023; D`Avila-Mesquita et al. 2021; Sleziak et al. 2024). This comprehensive study investigated gene and protein expression, DNA methylation, and microRNA (miRNA)-mediated regulation of molecules previously associated with COVID-19. Epigenetics, defined as heritable changes in the cellular phenotype that are independent of alterations to the DNA sequence (Waddington 2012), has emerged as a critical field in the understanding of the complexities of the SARS-CoV-2 virus and its associated disease, influencing susceptibility, severity, and outcomes (Xiao and Vermund 2024). DNA methylation, which is mediated by DNMT enzymes, is an epigenetic mechanism linked to immune response modulation and clinical outcomes in patients with COVID-19 (Bradic et al. 2022). DNMT activity is fundamental for both the establishment of DNA methylation and the maintenance of methylation patterns (Chiang et al. 1996). Dysregulation of DNMT expression and activity has been observed in numerous pathologies, highlighting the critical role of DNA methylation in health and disease. Owing to its reversibility and plasticity, DNA methylation is also a promising biomarker for disease monitoring and for identifying potential therapeutic targets (Bradic et al. 2022). In addition to DNA methylation, miRNAs also play important roles in regulating cellular processes. These small non-coding RNA molecules regulate gene expression by binding to complementary messenger RNA (mRNA) transcripts, either promoting their degradation or inhibiting translation, thereby acting as key transcriptional regulators in pathological contexts (Jackson and Standart 2007). Several studies have reported aberrant miRNA expression during the progression of COVID-19. Indeed, Fernández-Pato et al. identified 200 differentially expressed miRNAs in the plasma of COVID-19 patients, which were also found to be correlated with proinflammatory cytokines such as IL-6, IL-12, IL-10 and TNF-ɑ (Fernández-Pato et al. 2022). Therefore, this study aimed to characterize the expression and activity profiles of DNMTs, as well as the specific DNA methylation patterns, and to identify differentially expressed miRNAs involved in the pathogenesis of COVID-19. Although much remains to be understood about the epigenetic landscape in COVID-19, research in this field may provide valuable insights for developing novel therapeutic strategies and personalized treatments based on individual epigenetic profiles. Methods Reagents TRIzol (Cat No. 15596026) and Turbo DNAse I (Cat No. 2238G) were obtained from Invitrogen (California, USA), while SYBR Green Universal Master Mix (Cat No. 4309155) was obtained from Applied Biosystems (California, USA) and SuperSignal West Femto Substrate (Cat No. 34095) from Thermo Fisher Scientific (California, USA). QuantiNova Reverse Transcription Kit (Cat No. 205411), Epitec Plus Bisulfite Kit (Cat No. 59824), EvaGreen PCR Master Mix (Cat No. 250111), QIAquick Gel Extraction Kit (Cat No. 20021), miRNeasy Tissue/Cells Advanced Mini Kit (Cat No. 217604), miRCURY LNA RT Kit (Cat No. 339340), RNA Spike-in Kit (Cat No. 339390), miRCURY-LNA-miRNA QC‒PCR panel (Cat No. YAHS-999YC-2/339331) and miRCURY LNA miRNA Focus PCR Panel, Human Inflammatory Response & Autoimmunity Focus (Cat No. YAHS-205ZC-4 /339325) were obtained from Qiagen (Hilden, Germany). MethylFlash Global DNA Methylation (5-mC) ELISA Easy Colorimetric Kit (Cat No. P-1030-96), EpiQuik Nuclear Extraction Kit (Cat No. OP-0002-1) and EpiQuik™ DNMT Activity/Inhibition ELISA Easy Colorimetric Kit (Cat No. P-3009-96) were obtained from Epigentek (New York, USA). MS-SAFE protease and phosphatase inhibitors (Cat No. MSSAFE-1VL) was obtained from Sigma-Aldrich (Missouri, USA) and pGEM-T Easy vector (Cat No. A1360) was obtained from Promega (Wisconsin, USA). Study cohort Lung tissue samples were obtained through minimally invasive post-mortem biopsies from patients with confirmed SARS-CoV-2 infection at Marcelino Champagnat Hospital (Brazil) between June 2020 and August 2021 (n = 9). The samples (3 × 3 cm) were stored at − 80 °C until processing. The clinical data included sex, age (mean 64.22 ± 10.87 years), and length of hospitalization (mean 22 ± 9 days) (Table 1).Table 1Characteristics of the study cohortGenderAgeDays between admission and deathFemaleMale < 60 > 60 < 1011 to 29 > 30Absolute values2736162Relative frequency22%78%33%67%11%67%22% Table 1Characteristics of the study cohortGenderAgeDays between admission and deathFemaleMale < 60 > 60 < 1011 to 29 > 30Absolute values2736162Relative frequency22%78%33%67%11%67%22% Characteristics of the study cohort Data from patients were divided on the basis of sex, age, time between admission to the hospital and date of death, represented in absolute values and relative frequency. None of the patients had pre-existing comorbidities, and all deaths were attributed to complications of SARS-CoV-2 infection. The control sample (n = 1) consisted of lung tissue obtained from an adult Caucasian male individual who died from non-respiratory and non-inflammatory causes. The tissue was collected within the first 24 h post-mortem. All molecular analyses were performed on bulk lung tissue. This study was approved by the Local Ethical Committee (PUCPR), and informed consent was obtained from all the legal representatives. RT‒qPCR analysis Total RNA was extracted from the lung samples using TRIzol (Invitrogen) following tissue disruption with the TissueLyser LT (Qiagen). Approximately 2 µg of RNA was treated with Turbo DNAse I (Invitrogen), followed by cDNA synthesis using the QuantiNova Reverse Transcription Kit (Qiagen). The cDNAs were subjected to RT‒qPCR using 1 × SYBR Green Universal Master Mix (Applied Biosystems) on a StepOnePlus system (Applied Biosystems). The primer sequences are listed in Supplementary Table S1. Relative gene expression was calculated using the 2ˆ-ΔΔCT method. Histological and immunohistochemistry analysis Lung samples were fixed in 10% formaldehyde for 24 h, embedded in paraffin, sectioned and deparaffinized. Sections were stained with hematoxylin and eosin (H&E) for histopathological analysis or processed for immunohistochemistry. Histopathological analysis was performed by a trained pathologist, and fibrosis was assessed qualitatively, based on collagen deposition and fibroblast density. Immunohistochemistry was performed using specific antibodies (Supplementary Table S2). The slides were scanned with an Axio Scan. Z1 Slide Scanner (Zeiss, Jena, Germany) and analyzed using ZEN Blue Edition software (Zeiss, Jena, Germany). Ten random high-power fields (40x) per sample were evaluated. Immunostained areas were quantified using a semi-automated color segmentation method in Image Pro-Plus version 4.5 software (Media Cybernetics, Rockville, MD). Immunopositive areas (μm2) were normalized to the total tissue area and expressed as a percentage for statistical analysis. Western blotting analysis Approximately 70 mg of lung tissue was lysed in buffer containing MS-SAFE protease and phosphatase inhibitors (Sigma) using the TissueLyser LT (Qiagen). Fifty micrograms of protein were separated on a 7% SDS‒PAGE gel and transferred to a nitrocellulose membrane (Amersham, GE Healthcare). The membranes were blocked with 5% BSA and incubated with primary and HRP-conjugated secondary antibodies (Supplementary Table S2). Chemiluminescence detection was performed using SuperSignal West Femto substrate (Thermo Fisher), and images were analyzed with Image Studio Lite software, version 4.0 (LI-COR Biosciences). DNA extraction and sodium bisulfite treatment Lung tissues were homogenized in buffer containing RNase and proteinase K using the TissueLyser LT (Qiagen). The DNA was then purified and quantified using a NanoDrop™ Lite spectrophotometer (Thermo Scientific), and its quality was assessed by 0.8% agarose gel electrophoresis. Approximately 2 μg of DNA was bisulfite-converted using the Epitec Plus Bisulfite Kit (Qiagen), following the manufacturer’s instructions. Global methylation assay The global methylation profile was assessed using genomic DNA and the MethylFlash Global DNA Methylation (5-mC) ELISA Easy Colorimetric Kit (Epigentek), according to the manufacturer's instructions. The methylated fraction of DNA was detected using an anti-5-methylcytosine (5-mC) antibody (Epigentek) and quantified by measuring the absorbance at 450 nm. Detection of DNMT activity and inhibition DNMT activity was assessed using nuclear proteins extracted with the EpiQuik Nuclear Extraction Kit (Epigentek). Approximately 20 μg of nuclear protein was analyzed using the EpiQuik™ DNMT Activity/Inhibition ELISA Easy Colorimetric Kit (Epigentek), according to the manufacturer’s instructions. Methylated DNA was detected using an anti-5-methylcytosine antibody, and quantification was performed by measuring the absorbance at 450 nm. MSP-dPCR Methylation-specific PCR (MSP) using digital (dPCR) technology was performed to assess ADAM33 and ACE2 methylation. The primers for ADAM33 were selected from the literature (Seniski et al. 2009), whereas the primers for ACE2 were designed using MethPrimer (Supplementary Table S1). The reactions contained 50 ng of bisulfite-treated DNA, 0.4 μM of each oligonucleotide, and 1 × EvaGreen PCR Master Mix (Qiagen, Hilden, Germany). Methylated (M) and unmethylated (U) reactions were run in parallel using separate master mixes. Amplification was carried out on QIAcuity 24-well nanoplates (26,400 partitions) with the QIAcuity 5-plex Digital PCR System (Qiagen). The data were analyzed using QIAcuity Suite, and methylation rates were calculated from absolute quantification (copies/μL) according to formulas described in previous studies (Cardoso et al. 2024). ADAM17 CpG island methylation analysis The CpG island in the ADAM17 promoter was identified using CpGPlot and MethPrimer., primers to amplify this region were designed with Primer3Plus (Supplementary Table S1). The PCR products were purified using the QIAquick Gel Extraction Kit (Qiagen) and cloned into the pGEM-T Easy vector (Promega). Eight clones per patient were sequenced using universal or reverse primers with BigDye Terminator chemistry on a 3500XL sequencer (Applied Biosystems). The percentage of methylation was calculated as the number of methylated CpG sites divided by the total number of CpGs analyzed. Inflammatory miRNA panel The miRNA extraction was performed using with the miRNeasy Tissue/Cells Advanced Mini Kit (Qiagen), and cDNA synthesis was carried out with the miRCURY LNA RT Kit (Qiagen), including the RNA Spike-in Kit (Qiagen) for quality control. Sample quality was assessed using the miRCURY-LNA-miRNA QC‒PCR panel (Qiagen). miRNA expression related to the inflammatory response was analyzed using the miRCURY LNA miRNA Focus PCR Panel, Human Inflammatory Response & Autoimmunity Focus (Qiagen), which contains 96 pairs of pre-adsorbed oligonucleotides (Supplementary Table S3). The data were processed using GeneGlobe – miRCURY LNA miRNA PCR Data Analysis software (Qiagen), and pathway enrichment analysis was performed using the Panther classification system. Statistical analyses All the experiments were performed in triplicate. Statistical analyses were conducted using Mann–Whitney, one-way ANOVA, Kruskal–Wallis test or Student's t-test, as appropriate. For analyses involving multiple comparisons, p-values were adjusted using the Benjamini–Hochberg false discovery rate (FDR) method. P values less than 0.05 were considered statistically significant. Descriptive analyses for categorical variables were based on absolute and relative frequencies. All analyses were performed using GraphPad Prism 10 or RStudio. Results Global methylation and DNMT analyses Gene expression analysis revealed that DNMT1, DNMT3A, and DNMT3B were downregulated in patients with SARS-CoV-2 infection (p < 0.0001) (Fig. 1A). In contrast, the protein levels of DNMT3A and DNMT3B increased (p < 0.05), whereas those of DNMT1 did not significantly change (Fig. 1B). To address this discrepancy, DNMT enzymatic activity was assessed, revealing a significant reduction in most COVID-19 patients, with an average activity of 4.04 in the control group versus 1.4 in patients (p < 0.05) (Fig. 1C). Despite the increased protein levels of DNMT3A and DNMT3B, overall DNMT activity was reduced. Inhibition analysis revealed that five patients exhibited significant DNMT inhibition, whereas three patients showed no difference compared with the control group. On average, DNMT activity was inhibited by 89.96% in the COVID-19 group (p < 0.005) (Fig. 1D), suggesting that, in this cohort of fatal cases, SARS-CoV-2 infection may be associated with reduced DNMT activity, potentially affecting gene regulation through DNA methylation.Fig. 1A Relative gene expression of DNMT1, DNMT3A and DNMT3B. B Relative expression of the soluble proteins DNMT1, DNMT3A and DNMT3B. C DNMT activity (OD/h/mg) was measured individually in control patients and those with COVID-19. D Inhibition of DNMT activity (%) in COVID-19 patients compared with that in control group. E Global DNA methylation in the control group and in patients affected by COVID-19 (5-mC%) A Relative gene expression of DNMT1, DNMT3A and DNMT3B. B Relative expression of the soluble proteins DNMT1, DNMT3A and DNMT3B. C DNMT activity (OD/h/mg) was measured individually in control patients and those with COVID-19. D Inhibition of DNMT activity (%) in COVID-19 patients compared with that in control group. E Global DNA methylation in the control group and in patients affected by COVID-19 (5-mC%) To further rule out the possibility that DNMT inhibition was due to limited substrate availability, global levels of 5-methylcytosine (5-mC) were measured. A significant reduction was found in three patients, although no significant difference was observed at the group level (Fig. 1E), indicating that DNMT inhibition in this cohort does not appear to be attributable to substrate limitation. Assessment of molecules involved in the pathogenesis of SARS-CoV-2 Analysis of key molecules involved in SARS-CoV-2 infection in lung tissue revealed that ADAM17 exhibited reduced gene expression (p < 0.0005) but increased protein levels (p < 0.005) (Fig. 2A and B). Additionally, ACE2 expression was significantly elevated at both the mRNA and protein levels in COVID-19 patients (p < 0.005) (Fig. 2C and D).Fig. 2A Relative gene expression of ADAM17, ADAM33 and MMP2. B Relative soluble protein expression of ADAM17, ADAM33 and MMP2. C Relative gene expression of ACE2 and MMP9. D IHC protein levels of ACE2 and MMP9. E Methylation rates of ACE2 and ADAM33 gene promoters A Relative gene expression of ADAM17, ADAM33 and MMP2. B Relative soluble protein expression of ADAM17, ADAM33 and MMP2. C Relative gene expression of ACE2 and MMP9. D IHC protein levels of ACE2 and MMP9. E Methylation rates of ACE2 and ADAM33 gene promoters Metalloprotease analysis revealed that ADAM33 gene expression was unchanged, whereas ADAM33 protein expression was significantly decreased (p < 0.005). MMP2 did not affect gene expression but increased protein levels (p < 0.005). In contrast, MMP9 exhibited consistent increases in both gene (p < 0.005) and protein levels (p < 0.05) (Fig. 2A, B, C and D). Specific methylation of target genes Given the lack of research on the epigenetic regulation of ADAM33, ACE2, and ADAM17 in patients with COVID-19, we investigated their specific methylation profiles to better understand the observed gene and protein expression patterns (Fig. 2E). Our results revealed a substantial decrease in ACE2 promoter methylation compared with that in the control group (p < 0.0001) as well as a notable reduction in ADAM33 promoter methylation in COVID-19 patients (p < 0.0001). In contrast, the ADAM17 promoter showed no differential methylation between the groups, with no significant changes observed across the 22 CpG sites analyzed by sequencing, consequently, MSP-dPCR analysis could not be performed (data not shown). Inflammatory profile To assess the inflammatory status, the mRNA (Fig. 3A) and protein levels (Fig. 3B) of several important inflammatory markers were evaluated. ICAM1 gene expression remained unchanged, whereas its protein levels were significantly increased in patients with SARS-CoV-2 infection (p < 0.0001).Fig. 3A Relative gene expression of ICAM-1, TNF-α, COX-2, IL-6, TGFBR1 and TGFBR2. B Protein levels of ICAM, TNF-α, COX-2, IL-6 and TGF-β assessed by IHC. For IHC analysis, immunopositive areas were quantified in ten random high-power fields (HPF, 40×) per sample using a semi-automated color segmentation method and expressed as a percentage of the total tissue area A Relative gene expression of ICAM-1, TNF-α, COX-2, IL-6, TGFBR1 and TGFBR2. B Protein levels of ICAM, TNF-α, COX-2, IL-6 and TGF-β assessed by IHC. For IHC analysis, immunopositive areas were quantified in ten random high-power fields (HPF, 40×) per sample using a semi-automated color segmentation method and expressed as a percentage of the total tissue area TNF-α and IL-6 did not significantly change at either gene or protein level. COX-2 gene expression was upregulated (p < 0.05), whereas protein levels remained unchanged. Interestingly, TGFBR1 and TGFBR2 gene expression was markedly decreased (p < 0.0005), whereas TGF-β protein levels were significantly increased (p < 0.005). These results are consistent with our histological findings in this set of samples. Marked alveolar septal fibrosis was evident, accompanied by a chronic inflammatory process involving lymphocytes and numerous histiocytes (Fig. 4A and C). Plasmocytes, fibroblasts, blood vessels, and collagen fibers were also identified (Fig. 4B and D).Fig. 4A and C Photomicrographs of sections of lung tissue stained with hematoxylin and eosin at 10 × magnification. B and D are 20 × amplification photomicrographs of A and C, respectively A and C Photomicrographs of sections of lung tissue stained with hematoxylin and eosin at 10 × magnification. B and D are 20 × amplification photomicrographs of A and C, respectively miRNA analysis To further investigate epigenetic mechanisms, we analyzed the expression of 84 inflammation-related miRNAs. The relative expression values ranged from 0.17 to 61.94 across the control and COVID-19 groups (Fig. 5A). Two miRNAs, miR-16-5p and miR-30d-5p, were significantly downregulated in the COVID-19 group, whereas miR-19a-3p, miR-19b-3p and miR-21-5p were significantly upregulated (Fig. 5B).Fig. 5Expression profiles of miRNAs associated with inflammatory pathways in the lung tissues of the control and COVID-19 groups. A Heatmap displaying the expression (2−ΔΔCt) of 84 miRNAs relative to 10 endogenous miRNAs. B miRNAs differentially expressed in COVID-19 patients compared with controls (fold change > 2). Panels A and B are derived from the same dataset but represent different levels of analysis. Panel A provides a global overview of the dataset, whereas Panel B highlights only the miRNAs that were significantly differentially expressed. C Pathways modulated by differentially expressed miRNAs in the COVID-19 group. The size of each dot is proportional to the number of genes involved; the position along the y-axis reflects statistical significance, the closer the value is to p < 0.000, the higher the significance of the modulation; the x-axis reflects fold enrichment, which means the higher is the pathway, most differentially regulated Expression profiles of miRNAs associated with inflammatory pathways in the lung tissues of the control and COVID-19 groups. A Heatmap displaying the expression (2−ΔΔCt) of 84 miRNAs relative to 10 endogenous miRNAs. B miRNAs differentially expressed in COVID-19 patients compared with controls (fold change > 2). Panels A and B are derived from the same dataset but represent different levels of analysis. Panel A provides a global overview of the dataset, whereas Panel B highlights only the miRNAs that were significantly differentially expressed. C Pathways modulated by differentially expressed miRNAs in the COVID-19 group. The size of each dot is proportional to the number of genes involved; the position along the y-axis reflects statistical significance, the closer the value is to p < 0.000, the higher the significance of the modulation; the x-axis reflects fold enrichment, which means the higher is the pathway, most differentially regulated Integrative analysis of the molecular pathways modulated by the differentially expressed miRNAs revealed associations with key signaling pathways potentially involved in the immune response, tissue remodeling, and cellular homeostasis (Fig. 5C). These pathways include WNT, VEGF, TGF-β, PI3K, PDGF, p53, IFN-γ, IGF, FGF, EGF and CCKR. Additionally, pathways related to cell adhesion and communication, including those involving cadherins, integrins, endothelins, Toll-like receptors, α-adrenergic receptors, gonadotropin receptors, and glutamate receptors, were enriched. These results suggest that the differentially expressed miRNAs identified in this cohort may be involved in biological processes related to apoptosis, angiogenesis, T-cell activation, synaptic vesicle trafficking, hypoxia via HIF signaling, and axonal plasticity (Table 2).Table 2Functional classification of miRNAs differentially expressed in COVID-19 patients according to their regulatory pathways and biological processesPathway↓miR-16-5p↑ miR-19a-3p↑ miR-19b-3p↑ miR-21-5p↓miR-30d-5pInflammation/Immunity—↑ IL-6↑ TNF-α via NF-κB↑ IL-6↑ TNF-α via NF-κB↑ IL-6↑ IL-1β↑ TLR4↑ STAT3—Survival/Apoptosis/ProliferationPro-apoptotic↓ BCL2↓ Cyclin D1Pro-proliferation↓ PTEN↑ PI3K/AktPro-survival↓ PTENAnti-apoptosis↓ PTEN↓ PDCD4↑ PI3K/AktCell cycle inhibition↓ Cyclin E2↑ p21)Differentiation/EMT—EMT modulation↓ E-cadherin↑ VimentinEMT modulation↑ Tumoral invasion↑ EMT↑ Snail↓ E-cadherinEMT modulation↓ Snail↑ E-cadherinCellular Stress↑ ROS via SOD2Protector against DNA damage—↓ Antioxidants↑ ROSResponse to oxidative stress and hypoxiaAngiogenesis/Growth Factors↓ VEGFA↑ VEGF↑ HIF-1α↑ VEGF↑ VEGF↑ HIF-1α↓ DLL4/NotchCellular Adhesion/Tissue organization—↓ Epithelial addesion↓ Epithelial addesion↑ Fibrosis via TGF-β and SMAD7↓ IntegrinsOther pathwaysPI3K/AktWnt/β-cateninMAPK↑ STAT3↑ MYC↑ PI3K/Akt↑ JAK/STAT↑ TGF-β↑ RECK↑ STAT3↑ MMPs↓ Beclin-1Hypoxia-inducible pathways Table 2Functional classification of miRNAs differentially expressed in COVID-19 patients according to their regulatory pathways and biological processesPathway↓miR-16-5p↑ miR-19a-3p↑ miR-19b-3p↑ miR-21-5p↓miR-30d-5pInflammation/Immunity—↑ IL-6↑ TNF-α via NF-κB↑ IL-6↑ TNF-α via NF-κB↑ IL-6↑ IL-1β↑ TLR4↑ STAT3—Survival/Apoptosis/ProliferationPro-apoptotic↓ BCL2↓ Cyclin D1Pro-proliferation↓ PTEN↑ PI3K/AktPro-survival↓ PTENAnti-apoptosis↓ PTEN↓ PDCD4↑ PI3K/AktCell cycle inhibition↓ Cyclin E2↑ p21)Differentiation/EMT—EMT modulation↓ E-cadherin↑ VimentinEMT modulation↑ Tumoral invasion↑ EMT↑ Snail↓ E-cadherinEMT modulation↓ Snail↑ E-cadherinCellular Stress↑ ROS via SOD2Protector against DNA damage—↓ Antioxidants↑ ROSResponse to oxidative stress and hypoxiaAngiogenesis/Growth Factors↓ VEGFA↑ VEGF↑ HIF-1α↑ VEGF↑ VEGF↑ HIF-1α↓ DLL4/NotchCellular Adhesion/Tissue organization—↓ Epithelial addesion↓ Epithelial addesion↑ Fibrosis via TGF-β and SMAD7↓ IntegrinsOther pathwaysPI3K/AktWnt/β-cateninMAPK↑ STAT3↑ MYC↑ PI3K/Akt↑ JAK/STAT↑ TGF-β↑ RECK↑ STAT3↑ MMPs↓ Beclin-1Hypoxia-inducible pathways Functional classification of miRNAs differentially expressed in COVID-19 patients according to their regulatory pathways and biological processes ↑ IL-6 ↑ TNF-α via NF-κB ↑ IL-6 ↑ TNF-α via NF-κB ↑ IL-6 ↑ IL-1β ↑ TLR4 ↑ STAT3 Pro-apoptotic ↓ BCL2 ↓ Cyclin D1 Pro-proliferation ↓ PTEN ↑ PI3K/Akt Pro-survival ↓ PTEN Anti-apoptosis ↓ PTEN ↓ PDCD4 ↑ PI3K/Akt Cell cycle inhibition ↓ Cyclin E2 ↑ p21) EMT modulation ↓ E-cadherin ↑ Vimentin EMT modulation ↑ Tumoral invasion ↑ EMT ↑ Snail ↓ E-cadherin EMT modulation ↓ Snail ↑ E-cadherin ↓ Antioxidants ↑ ROS ↑ VEGF ↑ HIF-1α ↑ VEGF ↑ HIF-1α PI3K/Akt Wnt/β-catenin MAPK ↑ STAT3 ↑ MYC ↑ PI3K/Akt ↑ JAK/STAT ↑ TGF-β ↑ RECK ↑ STAT3 ↑ MMPs ↓ Beclin-1 Hypoxia-inducible pathways Discussion The dysregulation of molecules involved in disease progression may serve as valuable molecular markers to better understand the variability in disease severity among individuals. The gene and protein expression of DNMTs are altered in individuals with fatal COVID-19 in this cohort, while the enzymatic activity and inhibition of DNMTs are dysregulated, substrate availability remains unchanged, which is consistent with previous reports in the literature (Balnis et al. 2021). These findings suggest that the observed epigenetic modifications are likely a consequence of the disease process itself. Reduced DNMT1 levels can impair methylation maintenance during DNA replication, leading to passive DNA demethylation, in which methyl groups are gradually lost over successive cell divisions. Consequently, previously methylated regions may become hypomethylated (Piccolo and Fisher 2014). In contrast, downregulation of DNMT3A and DNMT3B can affect de novo methylation, resulting in decreased methylation at specific genomic loci (Okano et al. 1999). Previous studies have reported reduced DNMT activity in pulmonary epithelial cell lines infected in vitro with SARS-CoV-2 (Muhammad et al. 2021) and in peripheral blood samples from patients (Salem et al. 2023). However, this study extends these observations to lung tissue obtained from fatal cases of COVID-19. It has been previously shown that oxidative stress induced by SARS-CoV-2 infection depletes the levels of nicotinamide adenine dinucleotide phosphate (NADPH) and glutathione, leading to mammalian target of rapamycin (mTOR) activation, which further contributes to DNA methylation dysregulation through DNMT1 inhibition (Sethumadhavan et al. 2021). Another study revealed that the expression of all three DNMTs is inversely correlated with COVID-19 severity (Salem et al. 2023). Together, these findings support the hypothesis that SARS-CoV-2 infection may be associated with disruption of DNMT activity. They also suggested that although global DNA methylation levels are not significantly altered, locus-specific methylation changes may still occur in response to the disease. Despite the decreased gene expression of the DNMT genes, high levels of these proteins were detected. This may be because DNMT levels are dynamically controlled by multiple mechanisms, including allosteric interactions and post-translational modifications (Lin and Wang 2014). In the context of SARS-CoV infection, ADAM17 exhibits proteolytic activity against TNF-α and other membrane-bound proteins (Lambert et al. 2005). ADAM17 also plays a crucial role in regulating cytokine release and recruiting inflammatory cells. Its increased activity is associated with the cleavage of TNF-α, IL-1β, IL-6, and other pro-inflammatory molecules, which can exacerbate COVID-19 severity (Dreymueller et al. 2015). Hedges et al. demonstrated that blocking ADAM17 attenuates the inflammatory effects associated with severe symptoms of COVID-19 and that ADAM17 levels are elevated in severe cases (Hedges et al. 2022). Our findings are consistent with these reports, which revealed increased ADAM17 protein levels in this cohort of COVID-19 patients with poor outcomes. Furthermore, our results revealed no significant difference in the global methylation levels of the ADAM17 promoter between the control group and COVID-19 patients. Similarly, ADAM33 is involved in inflammatory processes and ECM remodeling in pulmonary diseases (Sleziak et al. 2024). Its soluble form promotes angiogenesis, contributing to airflow obstruction independently of inflammation (Davies et al. 2016). ADAM33 expression is restricted to mesenchymal cells, including airway fibroblasts, myofibroblasts, and smooth muscle cells, and its dysregulation is associated with airway remodeling and bronchial hyperresponsiveness (Davies et al. 2016). Epigenetic regulation of the ADAM33 gene via DNA methylation is well documented in chronic diseases, where its altered expression can influence disease severity (Manica et al. 2013). Other studies have reported higher ADAM33 protein levels in chronic lung diseases and pulmonary viral infections, including COVID-19 (Baurakiades et al. 2014), suggesting that this increase is associated with enhanced inflammatory responses, airway remodeling and fibrosis (Sleziak et al. 2024). These findings are consistent with our histological results. The reduced ADAM33 protein levels observed in our study may reflect the timing of sample collection and the patient's clinical status, as fibrosis had already been established (Baldi1, 2021 BG, Erico Tanni3 S. 2021). Thus, although the epigenetic marks that previously drove its previous upregulation remain, ADAM33 levels are no longer elevated. This observation is consistent with the gene and protein expression data, as promoter demethylation increases chromatin accessibility to the transcriptional machinery (Sethumadhavan et al. 2021). SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) receptor via its receptor-binding domain on the viral spike glycoprotein to enter host cells (Hooper et al. 2020). This interaction induces ACE2 internalization through the endosomal pathway, carrying viral particles and consequently reducing ACE2 tissue bioavailability (Hooper et al. 2020). Following viral entry, ACE2 downregulation leads to excessive ACE/Ang II activity, promoting increased vascular permeability, vasoconstriction, inflammation, and tissue damage (Hooper et al. 2020). Although reduced ACE2 expression has been hypothesized to limit viral entry, this remains controversial owing to the severe consequences associated with ACE2 deficiency (Zlacká et al. 2021). In addition to facilitating viral entry, ACE2 is involved in various aspects of COVID-19 pathogenesis and may contribute to post-infection sequelae. Previous studies have shown that higher ACE2 expression increases susceptibility to SARS-CoV-2 infection and is associated with poor COVID-19 prognosis (Yu et al. 2023). This aligns with our findings, as our cohort consisted of patients with fatal outcomes. Our findings on ACE2 promoter methylation are consistent with those of another study reporting reduced methylation levels in peripheral blood and bronchoalveolar lavage samples from individuals with COVID-19, which was associated with the occurrence of ARDS. Moreover, ACE2 hypomethylation has been linked to increased susceptibility to SARS-CoV-2 infection in patients with lupus (Sawalha et al. 2020). Lifestyle factors are also linked to ACE2 methylation and increased susceptibility to SARS-CoV-2 infection (Daniel et al. 2022). However, ACE2 methylation does not appear to correlate with prolonged symptoms after infection in hospitalized patients (Fernández-de-las-Peñas et al. 2024). Nevertheless, increased ADAM17 protein levels were observed in the COVID-19 group, corroborating the findings of previous studies and suggesting that ADAM17 regulation may occur through different mechanisms (Pomar et al. 2022). In addition to its metalloprotease function, ADAM17 plays a critical role in the context of SARS-CoV-2 infection, potentially facilitating viral entry by cleaving ACE2 during internalization (Pomar et al. 2022). Further research is needed to evaluate ADAM17 regulation in patients with severe cases of this disease. Although there is currently no scientific evidence describing the epigenetic profiles of ADAM17, ADAM33 and ACE2 in lung tissue from COVID-19 patients, a recent study reported that severe cases of the disease are associated with widespread DNA methylation changes in peripheral blood mononuclear cells. Epigenetic mechanisms have been shown to play crucial roles in lung diseases, particularly because the respiratory tract is continuously exposed to the external environment and is therefore especially susceptible to epigenetic modifications (Bradic et al. 2022). The demethylation observed in the ADAM33 and ACE2 promoters in the COVID-19 group can be explained by the reduced activity and increased inhibition observed in DNMTs, supporting findings from previous studies (Salem et al. 2023). Additionally, expression regulation is mediated by miRNAs, as we will discuss further. These molecules are directly involved in activating cytokines, cleaving cell signaling-related proteins, and exacerbating the inflammatory process in patients with COVID-19. MMP-2, along with MMP-9 and MMP-14, plays a role in epithelial remodeling and has been associated with pulmonary impairment. D'Avila Mesquita (D`Avila-Mesquita et al. 2021) reported that plasma levels of MMP-2 are significantly lower in patients with severe COVID-19 and are independently correlated with mortality. Therefore, further studies on the epigenetic regulation of MMP2 in the context of COVID-19 are warranted. Many of the molecules mentioned in this study are known to have well-defined epigenetic mechanisms in non-communicable chronic diseases, such as breast cancer. In breast cancer, MMP2 and MMP9 are regulated by DNA methylation, and their differential expression may influence disease severity (Klassen et al. 2018; Ramos et al. 2016). Since MMP-2 and MMP-9 can activate TGF-β by cleaving its latent form (Perng et al. 2011), this may partially explain the increased TGF-β found in our histological analysis. This analysis revealed recent fibrosis characterized by coarse collagen fibers and numerous activated fibroblasts forming multidirectional bundles. Together, these findings, along with the presence of plasma cells and newly formed vessels in the histological sections, are suggestive of remodeling of the alveolar septum. These findings corroborate previous studies on the role of metalloproteinases in SARS-CoV-2 infection (D`Avila-Mesquita et al. 2021). Downregulation of miR-16-5p was observed in COVID-19 patients. This miRNA has been described as a biomarker capable of distinguishing severe from mild viral infections (Giannella et al. 2022). In COVID-19, reduced levels of miR-16-5p exhibited over 90% sensitivity and specificity in distinguishing patients with the disease from healthy controls and were consistently decreased in moderate and severe cases (Giannella et al. 2022). Functionally, miR-16-5p modulates T-cell phenotypes and inflammatory signaling, including the IL-1β, IL-6, and TNF-α pathways, as well as the NF-κB and mTOR pathways (Hong et al. 2022). It also regulates MMP-2 and MMP-9 and has been implicated in the ACE2 regulatory network (Hong et al. 2022). Conversely, miR-30d-5p was significantly downregulated. The targets of miR-30d-5p encode enzymes involved in epigenetic and post-translational modifications, including DNMT3A (Fernández-Ponce et al. 2021). This finding reinforces the association between SARS-CoV-2 infection and dysregulation of DNMT expression and activity. Most studies have reported a downregulation of miR-30d-5p in COVID-19 patients, aligning with our findings (Nicoletti and S, Visacri MB, da Ronda CR da SC, Vasconcelos PE do NS, Quintanilha JCF, de Souza RN, Differentially expressed plasmatic microRNAs in Brazilian patients with Coronavirus disease 2019; Wilson et al. 2022). Loss of miR-30d-5p leads to the activation of the NF-κB, TGF-β/SMAD, and PI3K/AKT pathways, promoting increased inflammatory cytokine production (IL-6, TNF-α and IL-1β), which can lead to an exacerbated inflammatory response and fibroblast activation (Zeng et al. 2024). Additionally, miR-30d-5p modulates autophagy and apoptosis via mTOR signaling pathway (Fernández-Ponce et al. 2021). In addition, advanced-stage or extensively damaged lung tissues may exhibit reduced expression of miR-30d-5p, which is possibly associated with epithelial dysfunction and the progression of tissue remodeling (Fernández-Ponce et al. 2021). Although some miRNAs were downregulated in patients with SARS-CoV-2, the expression of miR-21-5p, miR-19a-3p and miR-19b-3p was increased, which is consistent with previous studies (Giannella et al. 2022; Gajate-Arenas et al. 2025). While data on miR-19a-3p and miR-19b-3p in relation to SARS-CoV-2 infection are scarce, both are known to inhibit TGF-β-mediated immunosuppressive signaling, which regulates regulatory T-cell induction, lymphocyte activation, and macrophage polarization (Li et al. 2021; Souma et al. 2018). Although these miRNAs play anti-inflammatory roles in some contexts, their persistent upregulation may contribute to cytokine dysregulation (Guiot et al. 2023), a central feature in the pathophysiology of severe COVID-19. miR-21-5p critically regulates proinflammatory pathways by activating the NLRP3 inflammasome. This activates caspase-1, which cleaves IL-1β and gasdermin D, thereby amplifying IL-6 and TNF-α (Xue et al. 2019). It also targets key modulators, such as PDCD4, E-cadherin, and TIMP2, that impact pathways including NF-κB, STAT3/5, and multiple interleukins (Xue et al. 2019), which are central to lung inflammation, tissue repair and regeneration. Consequently, higher levels of miR-21-5p may lead to worse outcomes of SARS-CoV-2 infection. Among the regulated pathways, p53, apoptosis and growth factor signaling (IGF, EGF, FGF, TGF and PDGF) stand out. Conversely, key vascular pathways related to vascular signaling (VEGF, endothelin and cadherin), T-cell activation and interferon (IFN) signaling are also regulated. EGFR is well known to be upregulated during acute lung injury, especially when STAT1 is deficient, leading to compensatory STAT3 overactivation (Venkataraman et al. 2017). Elevated EGFR and activated STAT3 suppress IFN signaling (Venkataraman et al. 2017), a mechanism that SARS coronaviruses exploit to inhibit IFN responses and facilitate viral replication (Park and Iwasaki 2020). Consequently, in patients with SARS-CoV-2 infection, EGFR-driven STAT3 activation likely compensates for impaired IFN-I production, contributing to hyperinflammation, thrombosis, lymphopenia, and fibrosis (Park and Iwasaki 2020). In addition to IFN suppression, the HIF-1α and IGF-1 pathways are regulated. IGF1 is essential for glucose metabolism (Santos et al. 2021) and has been linked to hyperglycemia and increased glycolysis in severe COVID-19. This metabolic reprogramming stabilizes HIF-1α through ROS production, thereby favoring viral replication (Santos et al. 2021). Moreover, this shift aligns with reports that increased IGF-1 and TGF signaling drive MMP9 expression in severe COVID-19 (Wang et al. 2023), which is consistent with our data. Wang et al. also reported IFN-α downregulation via the JAK/STAT and MAPK pathways, along with decreased Toll-like receptor expression (Wang et al. 2023), alterations that were also observed in our study. Furthermore, excessive cytokine activation disrupts homeostasis via the JAK/STAT pathway, resulting in elevated levels of IFN-γ, IL-2, IL-3, IL-5, IL-6, IL-8, IL-10, IL-12, and TNF (Wang et al. 2023). We also identified the regulation of angiogenesis, integrin signaling, and proliferative pathways, such as the WNT, RAS, and PI3K pathways. The activation of the WNT/β-catenin pathway, which involves β-catenin, T-cell factor, and lymphoid enhancer factor, has been associated with inflammation and fibrosis in lung injury models (Gatica-Andrades et al. 2017). In COVID-19, TGF-β further stimulates WNT/β-catenin, thereby exacerbating the risk of fibrosis, which is driven by processes such as EMT and fibroblast differentiation (Gatica-Andrades et al. 2017). The TGF-β and WNT/β-catenin pathways engage in a reciprocal positive feedback loop (Mehta and Baltimore 2016). ECM remodeling may activate TGF-β, enhancing integrin, thrombospondin, and STAT signaling (Lodyga and Hinz 2020), as well as fibrosis-associated genes, including integrins, proteoglycans, collagens, and MMPs (Xiao et al. 2022). Together, these findings suggest that persistent activation of the TGF-β pathway may contribute to pulmonary fibrosis in severe COVID-19. Recent studies have reported persistent immune and epigenetic dysregulation in individuals with long COVID or post-acute sequelae of SARS-CoV-2 infection (PASC), including sustained alterations in cytokine and interferon signaling (Santinelli et al. 2025), long-term immune and epigenetic remodeling detectable months after infection (Sidiropoulou et al. 2026), and persistent immunometabolic changes (Lage et al. 2025). Although our cohort consisted exclusively of fatal acute cases, the molecular patterns observed in lung tissue may reflect mechanisms that extend beyond the acute phase of infection. These parallels suggest that immune-epigenetic dysregulation could represent a broader feature of SARS-CoV-2 pathophysiology, warranting further investigation across different stages of disease. Our findings indicate that, in this cohort of fatal COVID-19 cases, SARS-CoV-2 infection is associated with epigenetic dysregulation in lung tissue, resulting in reduced DNMT activity and DNMT gene expression, independent of substrate availability. We observed hypomethylation in the promoters of ACE2 and ADAM33, which favors greater transcriptional accessibility. However, this was not always directly reflected at the mRNA or protein level, possibly because of the progression of the disease. There were also significant changes in miRNAs directly related to inflammation, fibrosis, tissue remodeling and immune response. Pathway analysis suggested potential activation of pro-fibrotic signaling and the suppression of interferon-mediated antiviral responses, highlighting the role of epigenetic and post-transcriptional regulation in SARS-CoV-2 infection and the long-term effects of disease. Collectively, these findings should be interpreted as exploratory and hypothesis-generating, providing a basis for future studies in larger and more diverse cohorts. Although preliminary, these findings may have potential translational relevance. The identified alterations in ECM regulators, epigenetic markers, and miRNA profiles could serve as candidate biomarkers for severe COVID-19–associated lung injury or as potential targets for therapeutic modulation. Future studies in larger and clinically stratified cohorts will be necessary to validate these molecular signatures and to determine their applicability in biomarker development and therapeutic research. Future studies using mechanistic approaches will be also necessary. Targeted modulation of DNMT activity or specific miRNAs in primary lung epithelial cells, fibroblasts, or organoid systems may help clarify their direct impact on ACE2, ADAM family members, metalloproteinases, and TGF-β signaling. Such approaches would be essential to determine whether the observed epigenetic and post-transcriptional alterations play a causal role in severe COVID-19 pathogenesis. Limitations of the study We acknowledge that the relatively small sample size represents a limitation of this study, due to the challenges of obtaining post-mortem lung biopsies from ICU patients under strict biosafety conditions during the COVID-19 peak, as well as the limited availability of patients without comorbidities. Similarly, obtaining control lung tissue from individuals who died of non-respiratory and non-inflammatory causes was difficult, given the need for rapid post-mortem processing, consent requirements, and scarcity of suitable cases. Additionally, the exact age of the control individual was not available. Therefore, this study should be considered descriptive and exploratory, with limited scope for validation. In addition to the limited sample size, other methodological constraints should be considered. Matched non-COVID-19 lung controls were not available for methylation and miRNA profiling analyses. Although samples were collected within a defined post-mortem interval, potential RNA degradation cannot be fully excluded. Moreover, the use of a preselected miRNA panel may have limited the identification of additional regulatory miRNAs not included in the assay. Finally, potential confounding factors such as post-mortem interval variability, viral load, and patients’ medication history may have contributed to heterogeneity in the multi-omics data and should be considered when interpreting the findings. Importantly, all molecular analyses were performed on bulk lung tissue samples. As such, the transcriptional and epigenetic alterations reported here represent aggregate signals derived from multiple cell populations, including epithelial, mesenchymal, endothelial, and immune cells. Consequently, interpretations regarding cell-type–specific mechanisms should be considered inferential and hypothesis-generating. Future studies employing spatial transcriptomics, single-cell RNA sequencing, or cell-type–specific isolation approaches will be necessary to delineate the precise cellular sources of these molecular alterations. Despite these constraints, we believe these results contribute valuable insights into the molecular mechanisms underlying COVID-19–related lung pathology and establish a solid foundation for future studies involving larger and more diverse cohorts. Conclusions In conclusion, our findings indicate that fatal COVID-19 may be associated with significant epigenetic and post-transcriptional dysregulation in lung tissue. Reduced DNMT activity and gene expression were accompanied by hypomethylation of the ACE2 and ADAM33 promoters and by alterations in miRNAs involved in inflammation, fibrosis, and tissue remodeling. Pathway analyses further suggested activation of pro-inflammatory and pro-fibrotic signaling alongside suppression of antiviral interferon responses. Although exploratory, these results highlight the potential role of epigenetic and miRNA-mediated mechanisms in severe COVID-19 pathogenesis and provide a basis for future studies investigating their potential as biomarkers or therapeutic targets. Supplementary Information Supplementary Material 1. Supplementary Material 2. Supplementary Material 1. Supplementary Material 2.